Biotricity Announces Cashflow Breakeven with Biggest Quarter in History and a Revenue Increase of 11%
Biotricity (OTCQB: BTCY), a Technology-as-a-Service company in remote cardiac monitoring, has announced strong financial performance for Q3-FY25. The company expects to report revenue of $3.6 million, representing a 22% year-over-year growth and an 11% sequential increase from the previous quarter.
The company will achieve positive cash flow for Q3-FY25 on current operating basis (before interest, dividends, and amortization), along with improved gross margins and operating results. This progress stems from their focus on automation, operating efficiency, and financial discipline while leveraging their Biocore suite of products and AI-driven solutions.
The full financial results will be released on February 19th, 2025, followed by a conference call on February 20th at 5:30 PM EST.
Biotricity (OTCQB: BTCY), un'azienda che offre tecnologia come servizio nel monitoraggio cardiaco remoto, ha annunciato una forte performance finanziaria per il terzo trimestre dell'anno fiscale 2025. L'azienda prevede di riportare entrate di 3,6 milioni di dollari, che rappresentano una crescita del 22% rispetto all'anno precedente e un aumento dell'11% rispetto al trimestre precedente.
L'azienda raggiungerà un flusso di cassa positivo per il terzo trimestre dell'anno fiscale 2025 su base operativa attuale (prima di interessi, dividendi e ammortamenti), insieme a margini lordi migliorati e risultati operativi. Questo progresso deriva dal loro focus su automazione, efficienza operativa e disciplina finanziaria, sfruttando al contempo la loro suite di prodotti Biocore e soluzioni basate sull'IA.
I risultati finanziari completi saranno pubblicati il 19 febbraio 2025, seguiti da una conferenza telefonica il 20 febbraio alle 17:30 EST.
Biotricity (OTCQB: BTCY), una empresa de Tecnología como Servicio en monitoreo cardíaco remoto, ha anunciado un sólido desempeño financiero para el tercer trimestre del año fiscal 2025. La empresa espera reportar ingresos de 3.6 millones de dólares, lo que representa un crecimiento del 22% en comparación con el año anterior y un aumento del 11% con respecto al trimestre anterior.
La empresa logrará un flujo de efectivo positivo para el tercer trimestre del año fiscal 2025 en base a la operación actual (antes de intereses, dividendos y amortización), junto con márgenes brutos mejorados y resultados operativos. Este progreso proviene de su enfoque en la automatización, la eficiencia operativa y la disciplina financiera, aprovechando su suite de productos Biocore y soluciones impulsadas por IA.
Los resultados financieros completos se publicarán el 19 de febrero de 2025, seguidos de una llamada de conferencia el 20 de febrero a las 5:30 PM EST.
Biotricity (OTCQB: BTCY), 원격 심장 모니터링 분야의 서비스형 기술 회사가 2025 회계연도 3분기 강력한 재무 성과를 발표했습니다. 이 회사는 360만 달러의 수익을 보고할 것으로 예상하며, 이는 전년 대비 22% 성장과 지난 분기 대비 11% 증가를 나타냅니다.
회사는 현재 운영 기준(이자, 배당금 및 감가상각 전)으로 2025 회계연도 3분기에 긍정적인 현금 흐름을 달성하고, 개선된 총 이익률과 운영 결과를 기록할 것입니다. 이러한 진전은 자동화, 운영 효율성 및 재무 규율에 대한 집중과 Biocore 제품군 및 AI 기반 솔루션을 활용한 결과입니다.
전체 재무 결과는 2025년 2월 19일에 발표되며, 2월 20일 오후 5시 30분 EST에 컨퍼런스 콜이 이어질 예정입니다.
Biotricity (OTCQB: BTCY), une entreprise de Technologie en tant que Service dans la surveillance cardiaque à distance, a annoncé de solides performances financières pour le troisième trimestre de l'exercice 2025. L'entreprise s'attend à déclarer un chiffre d'affaires de 3,6 millions de dollars, représentant une croissance de 22% par rapport à l'année précédente et une augmentation de 11% par rapport au trimestre précédent.
L'entreprise atteindra un flux de trésorerie positif pour le troisième trimestre de l'exercice 2025 sur une base opérationnelle actuelle (avant intérêts, dividendes et amortissements), avec des marges brutes et des résultats d'exploitation améliorés. Ce progrès découle de leur concentration sur l'automatisation, l'efficacité opérationnelle et la discipline financière tout en tirant parti de leur suite de produits Biocore et des solutions basées sur l'IA.
Les résultats financiers complets seront publiés le 19 février 2025, suivis d'une conférence téléphonique le 20 février à 17h30 EST.
Biotricity (OTCQB: BTCY), ein Technologie-as-a-Service-Unternehmen im Bereich der Fernüberwachung des Herzens, hat eine starke finanzielle Leistung für das 3. Quartal des Geschäftsjahres 2025 bekannt gegeben. Das Unternehmen erwartet, Einnahmen von 3,6 Millionen Dollar zu melden, was einem Wachstum von 22% im Vergleich zum Vorjahr und einem Anstieg von 11% im Vergleich zum vorherigen Quartal entspricht.
Das Unternehmen wird für das 3. Quartal des Geschäftsjahres 2025 einen positiven Cashflow auf der Grundlage des aktuellen Betriebs (vor Zinsen, Dividenden und Abschreibungen) erreichen, zusammen mit verbesserten Bruttomargen und Betriebsergebnissen. Dieser Fortschritt resultiert aus ihrem Fokus auf Automatisierung, Betriebseffizienz und finanzielle Disziplin, während sie ihre Biocore-Produktpalette und KI-gesteuerte Lösungen nutzen.
Die vollständigen finanziellen Ergebnisse werden am 19. Februar 2025 veröffentlicht, gefolgt von einer Telefonkonferenz am 20. Februar um 17:30 Uhr EST.
- Revenue growth of 22% year-over-year to $3.6 million
- 11% sequential revenue increase from previous quarter
- Achieved positive operating cash flow
- Improved gross margins and operating results
- Successfully implemented cost control measures
- None.
- Company expects to report Q3-FY25 revenue growth of
22% from the corresponding prior year quarter to$3.6 million – an11% increase sequentially from the immediately preceding quarter - Management continues to drive recurring revenue growth and efficiencies
- Company to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortization
- Company to report improved gross margins and operating results, as the Company nears its goal of achieving profitability
- Management to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST.
REDWOOD CITY, Calif., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today provided guidance on its financial results for the third quarter of fiscal 2025 year and (unaudited) ended December 31, 2024.
Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "In the third quarter of fiscal 2025, we continued our mission to develop innovative transformative healthcare technologies, while demonstrating our strong commitment to automation, operating efficiency and financial discipline. Our primary focus remains on driving revenue and margins and as such, we were pleased to see these metrics trend upwards. This quarter we continued to leverage our Biocore suite of products, and the data collected, pushing the boundaries of what's possible in healthcare outcomes through cutting-edge research and development. We continue our dedicated path of redefining medical diagnostics and patient care by introducing innovative AI-driven solutions.
The results for our third quarter demonstrate year-over-year and quarter-over-quarter revenue growth, as well as improvements in all key operating metrics. By growing our revenues, maintaining a strong focus on cost control to improve margins and reduce expenses, we continue to improve cash flow and have made consistent progress towards our goal of achieving profitability."
Financial Results and Business Update Conference Call
Management will host a conference call on Thursday, February 20th at 5:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://www.biotricity.com/investors/
Event: Biotricity Fiscal Third Quarter 2025 Results Release Conference Call
Date: Thursday, February 20, 2025
Time: 5:30 PM ET
Toll Free: 877-269-7751
International: 1-201-389-0908
Webcast URL:
http://callme.viavid.com/viavid/?callme=true&passcode=13747508&h=true&info=company&r=true&B=6
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-292
International: 1-412-317-6671
Replay Access ID: 13751857
Expiration: Thursday, March 06, 2025 at 11:59 PM ET
Full details of the Company’s financial results will be filed with the SEC on Form 10-Q on February 19, 2025, and available by visiting www.sec.gov thereafter.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
investors@biotricity.com
FAQ
What is Biotricity's (BTCY) expected revenue for Q3-FY25?
Has Biotricity (BTCY) achieved cash flow breakeven in Q3-FY25?
When will Biotricity (BTCY) release its Q3-FY25 financial results?
What is the sequential revenue growth for Biotricity (BTCY) in Q3-FY25?
What improvements did Biotricity (BTCY) report in Q3-FY25?
